Clinical correlates of raphe serotonergic dysfunction in early Parkinson's disease

Brain

Volumn 138, Issue 10, 2015, Pages 2964-2973

  Qamhawi, Zahi ^a   Towey, David ^a   Shah, Bina ^a   Pagano, Gennaro ^a   Seibyl, John ^b   Marek, Kenneth ^b   Borghammer, Per ^c   Brooks, David James ^a,c   Pavese, Nicola ^a,c  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b INSTITUTE FOR NEURODEGENERATIVE DISORDERS   (United States)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

non motor; Parkinson; serotonin; SPECT; tremor

Indexed keywords

DOPAMINE TRANSPORTER; FLUOROPROPYL CARBOMETHOXY 3 BETA 4 IODOPHENYLTROPANE I 123; RADIOPHARMACEUTICAL AGENT; SEROTONIN TRANSPORTER; UNCLASSIFIED DRUG; 2-CARBOMETHOXY-8-(3-FLUOROPROPYL)-3-(4-IODOPHENYL)TROPANE; SEROTONIN; TROPANE DERIVATIVE;

ADULT; AGED; ARTICLE; AUTONOMIC NEUROPATHY; CLINICAL EVALUATION; CONTROLLED STUDY; DAYTIME SOMNOLENCE; DEPRESSION; FATIGUE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEUROIMAGING; PARKINSON DISEASE; PRIORITY JOURNAL; RAPHE NUCLEUS; REM SLEEP; SEROTONINERGIC SYSTEM; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SLEEP DISORDER; TREMOR; UNIFIED PARKINSON DISEASE RATING SCALE; ANALYSIS OF VARIANCE; COHORT ANALYSIS; METABOLISM; MIDDLE AGED; NONPARAMETRIC TEST; OCCIPITAL LOBE; PATHOLOGY; SCINTISCANNING; SEVERITY OF ILLNESS INDEX; STATISTICS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; OCCIPITAL LOBE; PARKINSON DISEASE; RAPHE NUCLEI; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEVERITY OF ILLNESS INDEX; STATISTICS AS TOPIC; STATISTICS, NONPARAMETRIC; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 84947875160     PISSN: 00068950     EISSN: 14602156     Source Type: Journal    
DOI: 10.1093/brain/awv215     Document Type: Article

References (44)

1. Albin RL, Koeppe RA, Bohnen NI, Wernette K, Kilbourn MA, Frey KA. Spared caudal brainstem SERT binding in early Parkinsons disease. J Cereb Blood Flow Metab 2008; 28: 441-4.
2. Barone P. Neurotransmission in Parkinsons disease: beyond dopamine. Eur J Neurol 2010; 17: 364-76.
3. Berding G, Brucke T, Odin P, Brooks DJ, Kolbe H, Gielow P, et al. [123I]beta-CIT SPECT imaging of dopamine and serotonin transporters in Parkinsons disease and multiple system atrophy. Nuklearmedizin 2003; 42: 31-8.
4. Boileau I, Warsh JJ, Guttman M, Saint-Cyr JA, McCluskey T, Rusjan P, et al. Elevated serotonin transporter binding in depressed patients with Parkinsons disease: a preliminary PET study with [11C]DASB. Mov Disord 2008; 23: 1776-80.
5. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinsons disease. Neurobiol Aging 2003; 24: 197-211.
6. Caretti V, Stoffers D, Winogrodzka A, Isaias IU, Costantino G, Pezzoli G, et al. Loss of thalamic serotonin transporters in early drug-naive Parkinsons disease patients is associated with tremor: an [(123)I]beta-CIT SPECT study. J Neural Transm 2008; 115: 721-9.
7. Chinaglia G, Landwehrmeyer B, Probst A, Palacios JM. Serotoninergic terminal transporters are differentially affected in Parkinsons disease and progressive supranuclear palsy: an autoradiographic study with [3H]citalopram. Neuroscience 1993; 54: 691-9.
8. Dauer W, Przedborski S. Parkinsons disease: mechanisms and models. Neuron 2003; 39: 889-909.
9. de Win MM, Habraken JB, Reneman L, van den Brink W, den Heeten GJ, Booij J. Validation of [(123)I]beta-CIT SPECT to assess serotonin transporters in vivo in humans: a double-blind, placebo-controlled, crossover study with the selective serotonin reuptake inhibitor citalopram. Neuropsychopharmacology 2005; 30: 996-1005.
10. Doder M, Rabiner EA, Turjanski N, Lees AJ, Brooks DJ, 11C-WAY 100635 PET study. Tremor in Parkinsons disease and serotonergic dysfunction: an 11C-WAY 100635 PET study. Neurology 2003; 60: 601-5.
11. Dovzhenok A, Rubchinsky LL. On the origin of tremor in Parkinsons disease. PLoS One 2012; 7: e41598.
12. Fishman PS. Paradoxical aspects of parkinsonian tremor. Mov Disord 2008; 23: 168-73.
13. Guttman M, Boileau I, Warsh J, Saint-Cyr JA, Ginovart N, McCluskey T, et al. Brain serotonin transporter binding in nondepressed patients with Parkinsons disease. Eur J Neurol 2007; 14: 523-8.
14. Haapaniemi TH, Ahonen A, Torniainen P, Sotaniemi KA, Myllyla VV. 123I]beta-CIT SPECT demonstrates decreased brain dopamine and serotonin transporter levels in untreated parkinsonian patients. Mov Disord 2001; 16: 124-30.
15. Halliday GM, Blumbergs PC, Cotton RG, Blessing WW, Geffen LB. Loss of brainstem serotonin- and substance P-containing neurons in Parkinsons disease. Brain Res 1990; 510: 104-7.
16. Hesse S, Meyer PM, Strecker K, Barthel H, Wegner F, Oehlwein C, et al. Monoamine transporter availability in Parkinsons disease patients with or without depression. Eur J Nucl Med Mol Imaging 2009; 36: 428-35.
17. Hirsch EC, Orieux G, Muriel MP, Francois C, Feger J. Nondopaminergic neurons in Parkinsons disease. Adv Neurol 2003; 91: 29-37.
18. Hornung JP. The human raphe nuclei and the serotonergic system. J Chem Neuroanat 2003; 26: 331-43.
19. Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN, et al. Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab 2007; 27: 1533-9.
20. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540-5.
21. Kim SE, Choi JY, Choe YS, Choi Y, Lee WY. Serotonin transporters in the midbrain of Parkinsons disease patients: a study with 123Ibeta- CIT SPECT. J Nucleic Med 2003; 44: 870-6.
22. Kish SJ, Tong J, Hornykiewicz O, Rajput A, Chang LJ, Guttman M, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinsons disease. Brain 2008; 131: 120-31.
23. Kotagal V, Albin RL, Muller ML, Koeppe RA, Chervin RD, Frey KA, et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann Neurol 2012; 71: 560-8.
24. Lelieveld IM, Muller ML, Bohnen NI, Koeppe RA, Chervin RD, Frey KA, et al. The role of serotonin in sleep disordered breathing associated with Parkinson disease: a correlative [11C] DASB PET Imaging study. PloS one 2012; 7: e40166.
25. Loane C, Wu K, Bain P, Brooks DJ, Piccini P, Politis M. Serotonergic loss in motor circuitries correlates with severity of action-postural tremor in PD. Neurology 2013; 80: 1850-5.
26. Marek K. Beta-CIT scans without evidemce of dopaminergic deficit (SWEDD) in the ELLDOPA-CIT and CALM-cit study: long-term imaging assessment. Neurology 2003; 60: A293.
27. Marek K, Seibyl J, Eberly S, Oakes D, Shoulson I, Lang AE, et al. Longitudinal follow-up of SWEDD subjects in the PRECEPT Study. Neurology 2014; 82: 1791-7.
28. Molliver ME. Serotonergic neuronal systems: what their anatomic organization tells us about function. J Clin Psychopharmacol 1987; 7: 3S-23S.
29. Moore RY, Whone AL, Brooks DJ. Extrastriatal monoamine neuron function in Parkinsons disease: an 18F-dopa PET study. Neurobiol Dis 2008; 29: 381-90.
30. Murai T, Muller U, Werheid K, Sorger D, Reuter M, Becker T, et al. In vivo evidence for differential association of striatal dopamine and midbrain serotonin systems with neuropsychiatric symptoms in Parkinsons disease. J Neuropsychiatry Clin Neurosci 2001; 13: 222-8.
31. Olivier B, Soudijn W, van Wijngaarden I. Serotonin, dopamine and norepinephrine transporters in the central nervous system and their inhibitors. Prog Drug Res 2000; 54: 59-119.
32. Parkinson Progression Marker Initiative. The Parkinson Progression Marker Initiative (PPMI). Prog Neurobiol 2011; 95: 629-35.
33. Paulus W, Jellinger K. The neuropathologic basis of different clinical subgroups of Parkinsons disease. J Neuropathol Exp Neurol 1991; 50: 743-55.
34. Pavese N, Rivero-Bosch M, Lewis SJ, Whone AL, Brooks DJ. Progression of monoaminergic dysfunction in Parkinsons disease: a longitudinal 18F-dopa PET study. Neuroimage 2011; 56: 1463-8.
35. Pavese N, Metta V, Bose SK, Chaudhuri KR, Brooks DJ. Fatigue in Parkinsons disease is linked to striatal and limbic serotonergic dysfunction. Brain 2010; 133: 3434-43.
36. Pavese N, Metta V, Simpson B, Murphy T, Ramlackhansingh A, Chaudhuri K, et al. Sleep Regulatory Centres Dysfunction in Parkinsons disease patients with Excessive Daytime Sleepiness. Parkinsonism Relat Disord 2012; 18: S24-5.
37. Politis M, Wu K, Loane C, Kiferle L, Molloy S, Brooks DJ, et al. Staging of serotonergic dysfunction in Parkinsons disease: an in vivo 11C-DASB PET study. Neurobiol Dis 2010a; 40: 216-21.
38. Politis M, Wu K, Loane C, Turkheimer FE, Molloy S, Brooks DJ, et al. Depressive symptoms in PD correlate with higher 5-HTT binding in raphe and limbic structures. Neurology 2010b; 75: 1920-7.
39. Roselli F, Pisciotta NM, Pennelli M, Aniello MS, Gigante A, De Caro MF, et al. Midbrain SERT in degenerative parkinsonisms: a 123IFP- CIT SPECT study. Mov Disord 2010; 25: 1853-9.
40. Schwartz JR, Roth T. Neurophysiology of sleep and wakefulness: basic science and clinical implications. Curr Neuropharmacol 2008; 6: 367-78.
41. Selikhova M, Williams DR, Kempster PA, Holton JL, Revesz T, Lees AJ. A clinico-pathological study of subtypes in Parkinsons disease. Brain 2009; 132: 2947-57.
42. Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel- Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire-a new diagnostic instrument. Mov Disord 2007; 22: 2386-93.
43. Strecker K, Wegner F, Hesse S, Becker G, Patt M, Meyer PM, et al. Preserved serotonin transporter binding in de novo Parkinsons disease: negative correlation with the dopamine transporter. J Neurol 2011; 258: 19-26.
44. Weintraub D, Oehlberg KA, Katz IR, Stern MB. Test characteristics of the 15-item geriatric depression scale and Hamilton depression rating scale in Parkinson disease. Am J Geriatr Psychiatry 2006; 14: 169-75.